Patents by Inventor Thazha P. Prakash

Thazha P. Prakash has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210315918
    Abstract: Provided herein are methods, compounds, and compositions for modulation of transcript processing.
    Type: Application
    Filed: November 18, 2020
    Publication date: October 14, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Frank Rigo, Punit P. Seth
  • Publication number: 20210277401
    Abstract: Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.
    Type: Application
    Filed: May 11, 2020
    Publication date: September 9, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
  • Patent number: 11104899
    Abstract: Oligonucleotides, chemically-modified oligonucleotides, and oligonucleotide-conjugate complexes for use in research, diagnostics, and/or therapeutics are described herein. In some embodiments, oligonucleotides comprising a stabilized phosphate moiety covalently attached to the 5?-terminal nucleoside are provided.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: August 31, 2021
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Eric E. Swayze, Walter F. Lima, Garth A. Kinberger
  • Patent number: 11084844
    Abstract: The present invention provides modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides and analogs thereof that are useful for incorporation at the terminus of an oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: August 10, 2021
    Assignee: Ionis Pharmaceuticals, inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Publication number: 20210207146
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
    Type: Application
    Filed: August 4, 2020
    Publication date: July 8, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Sanjay Bhanot, Susan M. Freier, Huynh-Hoa Bui
  • Publication number: 20210130823
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Application
    Filed: June 24, 2020
    Publication date: May 6, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Publication number: 20210087566
    Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Application
    Filed: October 1, 2020
    Publication date: March 25, 2021
    Inventors: Thazha P. PRAKASH, Punit P. SETH, Eric E. SWAYZE, Mark J. GRAHAM
  • Publication number: 20210087559
    Abstract: Certain embodiments are directed to methods and compounds for increasing FXN. Such methods and compounds are useful for increasing expression of FXN in cells and animals.
    Type: Application
    Filed: December 21, 2018
    Publication date: March 25, 2021
    Inventors: Frank RIGO, Thazha P. PRAKASH, David COREY
  • Publication number: 20210052631
    Abstract: Provided herein are oligomeric compounds comprising a modified oligonucleotide and a conjugate group for modulating the amount or activity of a target nucleic acid in extra hepatic tissues and extra hepatic cells. Also provided herein are methods of modulating the amount or activity of an extra-hepatic nucleic acid target in a cell comprising contacting the cell with the oligomeric compound or antisense compound.
    Type: Application
    Filed: September 26, 2016
    Publication date: February 25, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Richard Lee, Punit P. Seth, Eric E. Swayze, Frank Rigo, Michael Oestergaard
  • Publication number: 20210054017
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to N-Acetylgalactosamine or to N-Acetylgalactosamine anaologues.
    Type: Application
    Filed: February 24, 2020
    Publication date: February 25, 2021
    Inventors: Punit P. Seth, Thazha P. Prakash, Michael T. Migawa, Eric E. Swayze
  • Patent number: 10927372
    Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apolipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: February 23, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
  • Publication number: 20210024923
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Application
    Filed: February 13, 2020
    Publication date: January 28, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 10883104
    Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: January 5, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
  • Patent number: 10875884
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: December 29, 2020
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
  • Publication number: 20200385722
    Abstract: The present invention provides 5? modified nucleosides and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides having at least one 5?-substituent and an optional 2? substituent, oligomeric compounds comprising at least one of these modified nucleosides and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: April 30, 2020
    Publication date: December 10, 2020
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 10844379
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: November 24, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Publication number: 20200325473
    Abstract: Disclosed are methods for modulating splicing of Ataxin 3 mRNA in an animal with modified oligonucleotides. Such compounds and methods are useful to treat, prevent, or ameliorate spinocerebellar ataxia type 3 (SCA3) in an individual in need thereof.
    Type: Application
    Filed: November 26, 2019
    Publication date: October 15, 2020
    Inventors: Frank RIGO, Thazha P. PRAKASH, Wilhelmina Maria Clasina VAN ROON-MOM, Lodewijk Julius Anton TOONEN
  • Patent number: 10793862
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: October 6, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Sanjay Bhanot, Susan M. Freier, Huynh-Hoa Bui
  • Publication number: 20200268898
    Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
    Type: Application
    Filed: November 7, 2018
    Publication date: August 27, 2020
    Inventors: Brett P. MONIA, Thazha P. PRAKASH, Garth A. KINBERGER, Richard LEE, Punit P. SETH, Michael OESTERGAARD, Mehran NIKAN, Shalini ANDERSSON, Eva Carina AMMALA, Daniel Laurent KNERR, Maria OLWEGARD-HALVARSSON, William John DRURY, III, Eric VALEUR
  • Publication number: 20200270609
    Abstract: The present disclosure pertains generally to chemically-modified oligonucleotides for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure describes compounds and methods for the modulation of a target nucleic acid. In certain embodiments, the present disclosure describes compounds and methods for the modulation of Apoliprotein C-III expression.
    Type: Application
    Filed: March 9, 2020
    Publication date: August 27, 2020
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Walter F. Lima, Garth A. Kinberger, Heather Murray, Eric E. Swayze, Stanley T. Crooke